Clinical pipeline ST-001 nanoFenretinide is in early phase trials for T-cell non-Hodgkin lymphoma with potential to expand to 15+ additional cancers, indicating opportunities to partner with oncology care centers and contract research organizations for trial expansion and co-development.

Funding runway Recent financing rounds totaling over 8 million between 2024 and 2025, plus ongoing capital expansion efforts, suggest availability of opportunities for strategic partnerships, licensing, or milestone-based collaborations to accelerate clinical development and manufacturing scale.

Leadership access New medical director and advisory board additions provide senior engagement points for potential collaborations, clinical trial design input, and advisory/consulting agreements with pharma and biotech stakeholders seeking expert oncology leadership.

Manufacturing readiness Scalable nanomanufacturing capabilities positioned to move ST-001 from lab to clinic offer opportunities to suppliers, contract manufacturers, and strategic partners for tech transfer, process development, and supply chain co-investments.

Clinical data visibility Ongoing Phase 1a results and presentations at major oncology forums (USCLC 2026, ASCO 2025) create openings for sponsorships, sponsored research agreements, or co-promotional programs with healthcare providers and payer organizations to demonstrate early efficacy and safe delivery.